KARYOPHARM THERAPEUTICS INC. (a Delaware corporation) · Shares of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • October 28th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations • New York
Karyopharm Therapeutics Inc., a Delaware corporation (the “Company”), confirms its agreements with Merrill Lynch, Pierce, Fenner & Smith Incorporated (“Merrill Lynch”), Leerink Swann LLC (“Leerink Swann”) and each of the other Underwriters named in Schedule A hereto (collectively, the “Underwriters,” which term shall also include any underwriter substituted as hereinafter provided in Section 10 hereof), for whom Merrill Lynch and Leerink Swann are acting as representatives (in such capacity, the “Representatives”), with respect to (i) the sale by the Company and the purchase by the Underwriters, acting severally and not jointly, of the respective numbers of shares of Common Stock, par value $0.0001 per share, of the Company (“Common Stock”) set forth in Schedule A hereto and (ii) the grant by the Company to the Underwriters, acting severally and not jointly, of the option described in Section 2(b) hereof to purchase all or any part of · additional shares of Common Stock to cover overal
KARYOPHARM THERAPEUTICS INC. INCENTIVE STOCK OPTION AGREEMENTIncentive Stock Option Agreement • October 28th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
KARYOPHARM THERAPEUTICS INC. NONSTATUTORY STOCK OPTION AGREEMENTNonstatutory Stock Option Agreement • October 28th, 2013 • Karyopharm Therapeutics Inc. • Pharmaceutical preparations
This option satisfies in full all commitments that the Company has to the Participant with respect to the issuance of stock, stock options or other equity securities.
